Program
Budesonide
Also written as “budesonide”, “budesonide/formoterol” and “BGF MDI 320/14.4/9.6 μg”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Eosinophilic Esophagitis · Colitis, Ulcerative · Glomerulonephritis, IGA, led by 35 companies.
Drug pageBudesonide: every studyMany companies study it; this page follows only the 163 they lead. All 307 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 692 open or running | phase 4since Sep 27, 2005 | Sep 13, 2005 | May 31, 2027phase 4 · NCT07073950 |
| Dr. Falk Pharmaits history only | 171 open or running | phase 3since Mar 7, 2006 | Mar 7, 2006 | Dec 2026phase 3 · NCT06596252 |
| Bausch Health Companiesits history only | 91 open or running | phase 4since Mar 17, 2020 | May 14, 2008 | Dec 2026phase 4 · NCT04314375 |
| Takedaits history only | 60 open or running | phase 3since Nov 4, 2015 | Sep 29, 2008 | none ahead |
| AbbVieits history only | 50 open or running | phase 3since Dec 5, 2007 | Oct 30, 2007 | none ahead |
| Calliditas Therapeutics ABits history only | 51 open or running | phase 4since Nov 20, 2024 | Oct 5, 2008 | Mar 2027phase 4 · NCT06712407 |
| Intech Biopharmits history only | 50 open or running | phase 2since Jun 11, 2014 | Jun 11, 2014 | none ahead |
| Chenpon Pharmaceuticalits history only | 30 open or running | phase 3since Aug 24, 2026 | Aug 24, 2026 | none ahead |
| Eurofarma Laboratoriosits history only | 30 open or running | phase 3since Oct 23, 2009 | Oct 23, 2009 | none ahead |
| Novartisits history only | 30 open or running | phase 4since Feb 15, 2013 | Feb 15, 2013 | none ahead |
| Orion Corporation, Orion Pharmaits history only | 30 open or running | phase 2since Aug 24, 2009 | Aug 24, 2009 | none ahead |
| Padagisits history only | 30 open or running | phase 3since Sep 28, 2011 | Sep 28, 2011 | none ahead |
| Aquilon Pharmaceuticalsits history only | 20 open or running | phase 2since May 31, 2021 | May 31, 2021 | none ahead |
| Bond Avillion 2 Development LPits history only | 20 open or running | phase 3since Nov 30, 2018 | Nov 30, 2018 | none ahead |
| Ferring Pharmaceuticalsits history only | 20 open or running | phase 3since Jan 22, 2018 | Jan 22, 2018 | none ahead |
| Ligand Pharmaceuticalsits history only | 20 open or running | phase 2since Jul 13, 2009 | Jul 13, 2009 | none ahead |
| Pari Pharmaits history only | 20 open or running | phase 2since Sep 4, 2013 | Sep 4, 2013 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 3since Feb 12, 2014 | Feb 12, 2014 | none ahead |
| Triastek, lnc.its history only | 22 open or running | phase 1since Oct 13, 2026 | Oct 13, 2026 | Dec 2026phase 1 · NCT07897240 |
| Vecturaits history only | 20 open or running | phase 1since Jan 12, 2018 | Jan 12, 2018 | none ahead |
| Zambon SpAits history only | 20 open or running | phase 1since Sep 2, 2014 | Sep 2, 2014 | none ahead |
| Abbottits history only | 10 open or running | phase 1since Jul 26, 2022 | Jul 26, 2022 | none ahead |
| Ache Laboratorios Farmaceuticosits history only | 10 open or running | phase 3since Jul 25, 2016 | Jul 25, 2016 | none ahead |
| Activaeroits history only | 10 open or running | phase 2since Sep 10, 2010 | Sep 10, 2010 | none ahead |
| Bazell Pharma | 10 open or running | phase 2since Jan 3, 2022 | Jan 3, 2022 | none ahead |
| Chiesi Farmaceuticiits history only | 10 open or running | phase 3since May 18, 2007 | May 18, 2007 | none ahead |
| Ciplaits history only | 10 open or running | phase 3since Mar 31, 2022 | Mar 31, 2022 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Apr 18, 2021 | Apr 18, 2021 | none ahead |
| Hamad Medicalits history only | 11 open or running | phase 3since May 25, 2015 | May 25, 2015 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 4since Oct 17, 2019 | Oct 17, 2019 | none ahead |
| Kindeva Drug Deliveryits history only | 10 open or running | phase 3since Jan 6, 2017 | Jan 6, 2017 | none ahead |
| Lunan Pharmaceutical Groupits history only | 10 open or running | no phasesince Mar 29, 2025 | Mar 29, 2025 | none ahead |
| Marinomed Biotechits history only | 10 open or running | phase 3since Nov 21, 2018 | Nov 21, 2018 | none ahead |
| Rafa Laboratoriesits history only | 10 open or running | phase 3since Aug 9, 2005 | Aug 9, 2005 | none ahead |
| Unither Pharmaceuticals, Franceits history only | 10 open or running | phase 1since Sep 6, 2024 | Sep 6, 2024 | none ahead |
Also a collaborator on its studies: Parexel, Fortrea, Takeda Development Center Americas, Iqvia Pty, Premier, Hikma Pharmaceuticals, Cosmo Technologies, MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan, Q-Pharm Pty and Kyowa Kirin.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bazell Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 3, 2022First study: phase 2 study in Eosinophilic EsophagitisFirst studyNCT05214599
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
The one study Bazell Pharma leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05214599Eosinophilic Esophagitis | 2 | Withdrawn | Nov 2024 | 0 |
How it is read
Names in the registry
- “Budesonide”, 45 entries
- “budesonide”, 18 entries
- “budesonide/formoterol”, 10 entries
- “BGF MDI 320/14.4/9.6 μg”, 6 entries
- “BFF MDI 320/9.6 μg”, 5 entries
Conditions, from the studies’ own filings
- Asthma, 75 studies
- Pulmonary Disease, Chronic Obstructive, 23 studies
- Eosinophilic Esophagitis, 10 studies
- Colitis, Ulcerative, 9 studies
- Glomerulonephritis, IGA, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.